These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 34843705)
1. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Malipiero G; D'Agaro P; Segat L; Moratto A; Villalta D Clin Chim Acta; 2022 Jan; 524():11-17. PubMed ID: 34843705 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination. Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095 [TBL] [Abstract][Full Text] [Related]
3. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers. Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824 [TBL] [Abstract][Full Text] [Related]
4. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220 [TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170 [TBL] [Abstract][Full Text] [Related]
6. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
7. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed? Stellini R; Gianello R; Gomarasca W Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649 [TBL] [Abstract][Full Text] [Related]
8. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766 [TBL] [Abstract][Full Text] [Related]
9. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19? Scaggs Huang F J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545 [TBL] [Abstract][Full Text] [Related]
10. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance. De Pace V; Bruzzone B; Ricucci V; Calcavecchia N; Guarona G; Giberti I; Costa E; Ogliastro M; Galano B; Nigro N; Murgia D; Nanni L; Orsi A Hum Vaccin Immunother; 2023 Aug; 19(2):2258632. PubMed ID: 37724517 [TBL] [Abstract][Full Text] [Related]
11. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination. Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623 [TBL] [Abstract][Full Text] [Related]
12. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P Front Immunol; 2022; 13():909910. PubMed ID: 35784321 [TBL] [Abstract][Full Text] [Related]
13. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800 [TBL] [Abstract][Full Text] [Related]
14. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651 [TBL] [Abstract][Full Text] [Related]
15. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205 [TBL] [Abstract][Full Text] [Related]
16. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390 [TBL] [Abstract][Full Text] [Related]
17. Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies. Caruso T; Salani F; Catanese S; Pratesi F; Mercinelli C; Motta G; Genovesi V; Bonato A; Sara G; Masi G; Migliorini P Int J Clin Oncol; 2023 Mar; 28(3):363-369. PubMed ID: 36689013 [TBL] [Abstract][Full Text] [Related]
18. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up. Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903 [TBL] [Abstract][Full Text] [Related]
19. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis. Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863 [TBL] [Abstract][Full Text] [Related]
20. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]